Psychological, Motor, Cognitive and Biological Benefits
Research on meditation and Parkinsonās is moving beyond stress reduction. Studies report benefits for anxiety, depression, quality of life, motor symptoms and cognition. Emerging research also points to biological effects involving dopamine, neuroplasticity and inflammation. The evidence remains limited and sometimes inconsistent, but suggests meditation deserves serious attention as a complementary therapy for Parkinsonās.
Meditation is hardly the first therapy that comes to mind for Parkinsonās disease. Exercise, physiotherapy and medication have much more obvious relationships to a movement disorder. Meditation is more readily associated with relaxation, stress reduction and emotional well-being.
Those benefits matter. Parkinsonās is not only a movement disorder. Anxiety, depression, cognitive changes and other non-motor symptoms can have a substantial effect on quality of life. Stress can also exacerbate motor symptoms such as tremor and freezing. Meditation therefore has an obvious place as a complementary practice for managing the psychological burden of living with Parkinsonās.
But the research is beginning to suggest something more interesting. Studies have reported changes not only in anxiety and depression, but also in motor symptoms, cognition, inflammatory biomarkers and even brain structure. Research outside Parkinsonās has also found that meditation can affect dopamine release, a finding of particular interest in a disease characterized by the progressive loss of dopamine-producing neurons.
Psychological Benefits
The strongest case for meditation begins with its psychological effects. Anxiety and depression are common non-motor symptoms of Parkinsonās, while the uncertainty and progressive nature of the disease create their own sources of stress.
A systematic review and meta-analysis by Yi et al. (2024), examining 12 studies, found statistically significant reductions in anxiety and depression among people with Parkinsonās receiving mindfulness-based interventions. The researchers also found improvements in mindfulness and quality of life. Notably, however, they did not find a statistically significant pooled effect on motor symptoms.
More recent research strengthens the psychological findings. A randomized clinical trial published in 2025 assigned 159 people with mild-to-moderate Parkinsonās to meditation, yoga or usual care. After eight weeks, both meditation and yoga significantly reduced anxiety compared with usual care. Meditation also significantly reduced depression (Kwok et al., 2025).
These may sound like the āsoftā benefits of meditation, but they should not be dismissed as peripheral to Parkinsonās. Stressful situations can worsen tremor and freezing, while anxiety and depression can compound the difficulties of living with the disease (Pickut et al., 2015). Reducing psychological distress is therefore worthwhile in itself and may also influence how Parkinsonās symptoms are experienced.
Motor Benefits
More surprising is evidence that meditation may affect motor symptoms themselves.
Pickut et al. (2015) conducted one of the early randomized controlled trials of mindfulness training in Parkinsonās. Thirty participants were randomized to an eight-week mindfulness-based intervention or usual care, with 27 completing the study. Motor performance was assessed by a movement-disorders specialist who was blinded to the participantsā treatment allocation.
The mindfulness group improved by 5.5 points on the motor section of the Unified Parkinsonās Disease Rating Scale (UPDRS-III), from 27.43 to 21.93āan improvement of about 20 percent. The usual-care group did not improve. The researchers noted that a five-point change had previously been proposed as a clinically meaningful improvement, although they also cautioned that their sample was small and placebo effects could not be excluded.
The evidence has since become stronger, although not entirely consistent. A 2023 systematic review and meta-analysis of eight randomized trials involving 337 people with Parkinsonās found that mindfulness and meditation interventions improved UPDRS-III scores by an average of 6.31 points compared with control conditions (Jin et al., 2023).
The larger 2025 randomized trial produced a similar result. Participants assigned to meditation improved significantly in motor symptoms compared with usual care, with a mean difference of 5.35 points after eight weeks. Perhaps more interestingly, the motor improvement in the meditation group remained significant at the six-month assessment (Kwok et al., 2025).
There is reason for caution. The 2024 meta-analysis by Yi et al. did not find a statistically significant overall motor effect. The studies use different interventions, outcome measures and populations, and many remain relatively small. The evidence therefore does not establish meditation as a motor treatment for Parkinsonās. But neither can its possible motor effects be readily dismissed.
Cognitive Benefits
Parkinsonās can also affect attention, executive function, memory and other aspects of cognition. Meditation is itself an exercise in attention, making cognitive effects particularly interesting.
The 2023 meta-analysis of randomized trials found a significant improvement in cognitive function among participants receiving mindfulness or meditation interventions, with a standardized mean difference of 0.62āa moderate effect (Jin et al., 2023).
The evidence here is much smaller than the broader literature on meditation and cognition, and it would be premature to conclude that meditation protects against Parkinsonās-related cognitive decline. Nevertheless, cognition deserves attention as a separate outcome of future Parkinsonās meditation research.
Quality of Life and Non-Motor Symptoms
Ultimately, an intervention for a chronic progressive disease should be judged not only by clinical measurements but also by whether it helps people live better.
The evidence here is mixed but encouraging. Yi et al. (2024) found a significant overall improvement in quality of life across mindfulness studies. The 2025 randomized trial similarly found significant improvements in health-related quality of life after meditation, with the benefit still detectable six months later (Kwok et al., 2025).
Results for individual symptoms such as pain, sleep and activities of daily living are less consistent. The 2023 meta-analysis, for example, did not find significant pooled improvements in sleep, pain or activities of daily living (Jin et al., 2023).
This distinction is important. Meditation should not become a catch-all therapy to which every positive outcome is attributed. The evidence is stronger for some effects than others.
Dopamine, Neuroplasticity and Inflammation
Some of the most intriguing research concerns measurable changes in the brain and body.
Dopamine provides an obvious point of interest in Parkinsonās. The disease is characterized by progressive loss of dopamine-producing neurons, and many of the most effective Parkinsonās medications work directly or indirectly on the dopaminergic system.
Kjaer et al. (2002) used PET imaging to study experienced practitioners during Yoga Nidra meditation. They observed a 7.9 percent reduction in 11C-raclopride binding in the ventral striatum, corresponding to an estimated 65 percent increase in endogenous dopamine release during meditation.
That figure is striking, but it needs careful interpretation. The participants were healthy meditators, not people with Parkinsonās. The study demonstrated an acute change in dopamine release during a particular meditation practice; it did not show that meditation increases the number of dopamine-producing neurons, reverses dopamine loss, or slows Parkinsonās disease.
The appropriate conclusion is modest but fascinating: meditation can influence dopaminergic activity in the human brain. Whether that mechanism contributes to any of the motor improvements observed in Parkinsonās meditation studies remains unknown.
There is also Parkinsonās-specific evidence suggestive of neuroplasticity. Pickut et al. (2013) used MRI to examine people with Parkinsonās before and after an eight-week mindfulness intervention. Compared with usual care, the mindfulness group showed increased grey matter density in several areas, including the hippocampus, amygdala, caudate nucleus and thalamus. These regions are involved in functions including memory, emotion and movement.
The study was very smallā27 participants completed itāand its statistical results were reported without correction for multiple comparisons. It should therefore be regarded as exploratory rather than proof that meditation reverses Parkinsonās-related brain changes. Nevertheless, it demonstrates that meditation-related structural brain changes can be investigated directly in people with Parkinsonās rather than inferred solely from research involving healthy meditators.
Inflammation provides another possible biological pathway. In the 2025 randomized Parkinsonās trial, researchers measured inflammatory and stress biomarkers. Both the meditation and yoga groups subsequently showed significant reductions in interleukin-6 (IL-6), an inflammatory marker (Kwok et al., 2025).
Again, this does not demonstrate that meditation slows Parkinsonās neurodegeneration. But taken together, the dopamine, neuroplasticity and inflammation findings suggest that meditation is associated with measurable biological changes as well as subjective psychological ones.
Limits of the Evidence
Meditation research in Parkinsonās remains young. Many studies have small samples, interventions vary considerably, and āmeditationā may include mindfulness meditation, body scanning, yoga and other practices. Most studies have also concentrated on people with mild-to-moderate Parkinsonās rather than advanced disease.
There are also contradictory findings. One meta-analysis finds significant motor and cognitive benefits while another finds significant psychological and quality-of-life benefits but no significant motor effect. Such differences are not necessarily evidence that meditation does not work. They indicate that the evidence is not yet mature enough to determine reliably which forms of meditation help which symptoms, for whom, and by how much.
Most importantly, there is currently no convincing evidence that meditation slows the underlying neurodegenerative progression of Parkinsonās. Meditation should therefore be regarded as a complement to established medical treatment and exercise, not a substitute for them.
Meditation Beyond Relaxation
The safest conclusion from the research is also more interesting than I expected. Meditation appears to help people with Parkinsonās manage anxiety, depression and quality of life. There is promising, though less settled, evidence of benefits to motor symptoms and cognition. Small neurological studies have found measurable changes in brain structure and inflammatory markers, while research in healthy meditators demonstrates that meditation can influence dopamine release.
None of this makes meditation a cure for Parkinsonās. But it does suggest that describing meditation simply as a way to relax understates what may be happening.
The research is still developing. For people living with Parkinsonās, however, there is already enough evidence to take meditation seriously as a complementary practiceāand enough unanswered questions to make further research particularly worthwhile.
See also, Practising Meditation with Parkinsonās
References
Jin, X., Wang, L., Liu, S., Zhu, L., & Loprinzi, P. D. (2023). Mindfulness or meditation therapy for Parkinsonās disease: A systematic review and meta-analysis of randomized controlled trials. European Journal of Neurology. https://pubmed.ncbi.nlm.nih.gov/37158296/
Kjaer, T. W., Bertelsen, C., Piccini, P., Brooks, D., Alving, J., & Lou, H. C. (2002). Increased dopamine tone during meditation-induced change of consciousness. Cognitive Brain Research, 13(2), 255ā259. https://pubmed.ncbi.nlm.nih.gov/11958969/
Kwok, J. Y. Y., et al. (2025). Effects of meditation and yoga on anxiety, depression and chronic inflammation in patients with Parkinsonās disease: A randomized clinical trial. https://pubmed.ncbi.nlm.nih.gov/40024243/
Pickut, B. A., Van Hecke, W., Kerckhofs, E., MariĆ«n, P., Vanneste, S., Cras, P., & Parizel, P. M. (2013). Mindfulness based intervention in Parkinsonās disease leads to structural brain changes on MRI: A randomized controlled longitudinal trial. Clinical Neurology and Neurosurgery, 115(12), 2419ā2425. https://doi.org/10.1016/j.clineuro.2013.10.002
Pickut, B., Vanneste, S., Hirsch, M. A., Van Hecke, W., Kerckhofs, E., MariĆ«n, P., Parizel, P. M., Crosiers, D., & Cras, P. (2015). Mindfulness training among individuals with Parkinsonās disease: Neurobehavioral effects. Parkinsonās Disease, 2015, 816404. https://doi.org/10.1155/2015/816404
Yi, M., Zhang, W., Zhao, B., & Wang, Z. (2024). The effects of mindfulness-based interventions in people with Parkinsonās disease: A systematic review and meta-analysis. Clinical Gerontologist. https://doi.org/10.1080/07317115.2024.2314192
Last Updated on September 9, 2026 | Published: September 8, 2026